Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/11/2018 |
| Start Date: | July 21, 2015 |
| End Date: | December 31, 2022 |
| Contact: | Melanie Hughes |
| Email: | office@wcibmi.org |
| Phone: | 614-293-9998 |
The purpose of this study is to assess new low radiation dose techniques for clinical PET/CT
scans through intra-individual comparison between a clinical, standard dose scan and a
low-dose scan, completed within one week of each other.
scans through intra-individual comparison between a clinical, standard dose scan and a
low-dose scan, completed within one week of each other.
Positron Emission Tomography/Computed Tomography (PET/CT) imaging using 18F-FDG is an
important, commonly used cancer, neuroscience and cardio-vascular imaging methodology to
detect disease and to monitor therapeutic interventions. While considerable technological
progress of PET/CT systems has occurred over the last decade, we have not re-evaluated the
ability to potentially reduce the radiation burden of the used PET imaging pharmaceutical
(FDG).
This early phase trial intends to accomplish the following:
- to validate that the radiation dose burden from the PET imaging pharmaceutical (FDG) can
be reduced by more than 50% from the current standard of clinical care (SOC) level
without affecting the diagnostic ability;
- to confirm that a low dose approach will be feasible for response assessment;
- to validate that the difference in FDG uptake between imaging 60 min +/- 10 min post
injection and 75 min +/- 10 min post injection is independent/equivalent of the injected
FDG dose
- to validate a simulation methodology to streamline future dose finding studies for PET
imaging pharmaceuticals.
important, commonly used cancer, neuroscience and cardio-vascular imaging methodology to
detect disease and to monitor therapeutic interventions. While considerable technological
progress of PET/CT systems has occurred over the last decade, we have not re-evaluated the
ability to potentially reduce the radiation burden of the used PET imaging pharmaceutical
(FDG).
This early phase trial intends to accomplish the following:
- to validate that the radiation dose burden from the PET imaging pharmaceutical (FDG) can
be reduced by more than 50% from the current standard of clinical care (SOC) level
without affecting the diagnostic ability;
- to confirm that a low dose approach will be feasible for response assessment;
- to validate that the difference in FDG uptake between imaging 60 min +/- 10 min post
injection and 75 min +/- 10 min post injection is independent/equivalent of the injected
FDG dose
- to validate a simulation methodology to streamline future dose finding studies for PET
imaging pharmaceuticals.
Inclusion Criteria:
- Male and female patients greater than or equal to 18 years of age
- Patients scheduled for a standard of care PET/CT scan
- For female patients of child-bearing potential, the OSUWMC requirements for receiving
the standard of care PET imaging agent and CT examination needs to be met
Exclusion Criteria:
- Participants who are pregnant or lactating
- Prisoners
- Participants incapable of giving informed consent
- Patients unable to lie flat on the scanner for extended periods of time
We found this trial at
1
site
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
Click here to add this to my saved trials
